Citadel Advisors
CSTL icon

Citadel Advisors’s Castle Biosciences CSTL Stock Holding History

Citadel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.33M Buy
265,353
+144,376
+119% +$3.22M ﹤0.01% 4313
2026
Q1 		$2.97M Sell
120,977
-245,379
-67% -$8.04M ﹤0.01% 5285
2025
Q4 		$14.3M Buy
366,356
+115,441
+46% +$3.72M ﹤0.01% 2771
2025
Q3 		$5.71M Sell
250,915
-637,600
-72% -$13M ﹤0.01% 4124
2025
Q2 		$18.1M Buy
888,515
+630,133
+244% +$11.7M ﹤0.01% 2264
2025
Q1 		$5.17M Sell
258,382
-576,130
-69% -$14.3M ﹤0.01% 3814
2024
Q4 		$22.2M Buy
834,512
+201,496
+32% +$6.14M ﹤0.01% 2056
2024
Q3 		$18.1M Sell
633,016
-60,369
-9% -$1.54M ﹤0.01% 2153
2024
Q2 		$15.1M Buy
693,385
+37,619
+6% +$838K ﹤0.01% 2307
2024
Q1 		$14.5M Buy
655,766
+327,017
+99% +$7.11M ﹤0.01% 2436
2023
Q4 		$7.09M Sell
328,749
-189,309
-37% -$3.33M ﹤0.01% 3304
2023
Q3 		$8.75M Buy
518,058
+461,775
+820% +$8.08M ﹤0.01% 2859
2023
Q2 		$772K Sell
56,283
-604,673
-91% -$12.3M ﹤0.01% 6998
2023
Q1 		$15M Buy
660,956
+109,641
+20% +$2.68M ﹤0.01% 2270
2022
Q4 		$13M Sell
551,315
-181,340
-25% -$4.2M ﹤0.01% 2463
2022
Q3 		$19.1M Buy
732,655
+102,059
+16% +$2.86M ﹤0.01% 1920
2022
Q2 		$13.8M Buy
630,596
+443,589
+237% +$10.3M ﹤0.01% 2273
2022
Q1 		$8.39M Buy
187,007
+89,121
+91% +$3.68M ﹤0.01% 3246
2021
Q4 		$4.2M Sell
97,886
-132,553
-58% -$6.93M ﹤0.01% 4648
2021
Q3 		$15.3M Buy
230,439
+170,434
+284% +$12M ﹤0.01% 2403
2021
Q2 		$4.4M Sell
60,005
-87
-0.1% -$5.75K ﹤0.01% 4713
2021
Q1 		$4.11M Buy
60,092
+50,103
+502% +$3.77M ﹤0.01% 4704
2020
Q4 		$670K Sell
9,989
-49,807
-83% -$2.7M ﹤0.01% 7578
2020
Q3 		$3.08M Sell
59,796
-1,606
-3% -$71.4K ﹤0.01% 3944
2020
Q2 		$2.31M Buy
+61,402
New +$2.1M ﹤0.01% 4316
2020
Q1 		– Sell
-8,900
Closed -$305K – 9655
2019
Q4 		$305K Sell
8,900
-21,775
-71% -$532K ﹤0.01% 7552
2019
Q3 		$555K Buy
+30,675
New +$680K ﹤0.01% 6567

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's CSTL Position: Q2 2026 in Review

Citadel Advisors increased its Castle Biosciences (CSTL) stake by 119% in Q2 2026, buying an estimated $3.22M and bringing the position to 265,353 shares worth $6.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4313.

Citadel Advisors first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $22.2M in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Citadel Advisors held 265,353 shares of Castle Biosciences worth $6.33M as of Q2 2026.
  • Citadel Advisors bought 144,376 Castle Biosciences shares in Q2 2026, an estimated $3.22M.
  • Castle Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4313 holding.
  • Citadel Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Castle Biosciences position peaked at $22.2M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.